O'Melveny & Myers, Tian Yuan Law Firm and William Ji & Co. have represented China’s Simcere Pharmaceutical Group on its HK$3.57 billion ($460.6 million) Hong Kong IPO, with Herbert Smith Freehills and Jingtian & Gongcheng advising the joint sponsors.

The listing is the latest by a Chinese biopharmaceutical company in Hong Kong, which is on track to have its second-busiest year for equity capital markets ever in 2020. Recent such issuers include JHBP (CY) Holdings and Everest Medicines.

Simcere Pharmaceutical supplies branded generic pharmaceuticals to the Chinese market. It has increased investment in R&D in recent years, and has three R&D centres in Nanjing, Shanghai and Boston.

Partners Matt Emsley, Siddhartha Sivaramakrishnan and Stanley Xie led the Herbert Smith Freehills team.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com. 

Related Articles

Features

BRIEF: Malaysia Offers Investors Cooling IPO Respite During Sluggish Summer

by Sarah Wong |

In a year when global IPO markets have wilted under the economic heat, Bursa Malaysia has stood out as a surprising oasis of activity.

Deals

JSA, Trilegal act on NTPC Green’s upcoming $1.2bln IPO

by Nimitt Dixit |

JSA Advocates & Solicitors is advising NTPC Green Energy, state-run power producer National Thermal Power Corporation’s renewable energy arm, on its announced initial public offering worth $1.2 billion, with Trilegal advising the book running lead managers.

Deals

CAM, Khaitan, Links act on Bajaj Housing Finance’s $782mln IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Indian home-loan financier Bajaj Housing Finance (BHF) and its promoter Bajaj Finance on BHF’s $782 million initial public offering, with Khaitan & Co and Linklaters representing the book-running lead managers to the offer.